[
  {
    "trial": "FAME3",
    "nct": "NCT02100722",
    "n_pci": 757,
    "n_cabg": 743,
    "stable_n_pci": 456,
    "stable_n_cabg": 454,
    "acs_n_pci": 300,
    "acs_n_cabg": 287,
    "presentation_missing": 3,
    "stent": "Resolute Integrity or Resolute Onyx zotarolimus-eluting",
    "strategy": "FFR-guided PCI; intravascular imaging used in 11%",
    "followup_years": 5,
    "stable_outcomes_available": true,
    "lost_or_withdrawn_pci": 33,
    "lost_or_withdrawn_cabg": 47,
    "stable_missing_by_arm_reported": false,
    "sources": [
      "doi:10.1016/S0140-6736(25)00505-7",
      "doi:10.1016/j.jcin.2025.01.434"
    ],
    "source_locator": "Five-year report Table 2, Figure 1; appendix Table S9, printed page 22 (PDF page 23); three-year presentation report Table 1",
    "note": "Table S9 labels the non-ACS subgroup stable angina; presentation report calls it CCS. Do not include the three missing-presentation participants in either subgroup. S9 crude percentages and Cox HRs are different estimands."
  },
  {
    "trial": "HREVS",
    "nct": "NCT01699048",
    "n_pci": 53,
    "n_cabg": 50,
    "stable_n_pci": 53,
    "stable_n_cabg": 50,
    "acs_n_pci": 0,
    "acs_n_cabg": 0,
    "presentation_missing": 0,
    "stent": "Xience everolimus-eluting cobalt-chromium",
    "strategy": "Angiography/functionally selected PCI; hybrid arm excluded from this comparison",
    "followup_years": 5,
    "stable_outcomes_available": true,
    "lost_or_withdrawn_pci": 4,
    "lost_or_withdrawn_cabg": 3,
    "stable_missing_by_arm_reported": true,
    "observed_n_pci": 49,
    "observed_n_cabg": 47,
    "sources": [
      "doi:10.1155/2020/5458064",
      "doi:10.18087/cardio.2023.11.n2475"
    ],
    "source_locator": "Five-year report Methods and Table 3, printed pages 58-61 (PDF pages 2-5)",
    "note": "ACS and left-main disease explicitly excluded. Small single-center trial powered for residual ischemia, not clinical events. Published Table 3 uses complete-case denominators 49 and 47. Registry enrollment 150 differs from publication 155 including hybrid; use publication randomized arms."
  },
  {
    "trial": "BEST",
    "nct": "NCT00997828",
    "extended_nct": "NCT05125367",
    "n_pci": 438,
    "n_cabg": 442,
    "stable_angina_n_pci": 210,
    "stable_angina_n_cabg": 204,
    "unstable_angina_n_pci": 185,
    "unstable_angina_n_cabg": 199,
    "recent_mi_n_pci": 7,
    "recent_mi_n_cabg": 3,
    "other_presentation_n_pci": 36,
    "other_presentation_n_cabg": 36,
    "stent": "Xience everolimus-eluting",
    "strategy": "Angiography-guided PCI; IVUS used in 71.8%",
    "followup_years": 11.8,
    "followup_type": "median, not a common fixed horizon",
    "stable_outcomes_available": false,
    "sources": [
      "doi:10.1056/NEJMoa1415447",
      "doi:10.1161/CIRCULATIONAHA.122.062188",
      "doi:10.1016/j.jcin.2023.07.028"
    ],
    "source_locator": "Original Methods; extended abstract; extended diabetes report Tables 1 and 4",
    "note": "Trial terminated early after 880/1776 planned randomized participants. Stable angina counts sum mutually exclusive diabetes strata; other presentation is the arithmetic residual and is not assumed to be stable. No usable stable-only mortality/MI/stroke count table located in retrieved reports. Overall extended count data sum diabetes strata and are secondary mixed-presentation evidence. Registry actual enrollment 888 is not substituted for published randomized 880."
  }
]
